The safeguarding principle for anogenital warts in children is one of the most important medicolegal aspects of primary care management — while HPV can be transmitted perinatally (vertical transmission from an infected mother during vaginal delivery) and can present as anogenital warts in children up to approximately age 3, the presence of anogenital warts in any child beyond infancy, or in any child without a clear vertical transmission history, must trigger a safeguarding referral. The diagnosis of anogenital warts in a child aged 3+ is a potential marker of sexual abuse until a full safeguarding assessment excludes it. The safeguarding referral should be made at the same visit as identifying the lesions — not after treatment has been started. Treatment of the warts should not proceed before a safeguarding assessment is completed. Bowenoid papulosis deserves specific emphasis because it is the most common high-grade dysplastic condition that is misdiagnosed as common warts — it affects young sexually active adults, presents as multiple flat pigmented or red-brown papules on the glans, prepuce, or vulva, and is caused by HPV 16. Despite its benign clinical appearance (it rarely progresses to invasive SCC in immunocompetent adults), it represents VIN3/PIN3 histologically and requires specialist management with biopsy confirmation.

The distinction between HPV 6/11 (low-risk, causing condylomata acuminata) and HPV 16/18 (high-risk, causing cervical, vulval, penile, anal, and oropharyngeal cancers) is the fundamental clinical distinction in anogenital HPV disease. Visible genital warts are almost always caused by low-risk types (6/11) and carry negligible risk of malignant transformation — they cause significant psychological distress and physical symptoms but are not a cancer precursor. High-risk HPV causes invisible (subclinical) infection of the cervical transformation zone and anogenital epithelium, which can progress to dysplasia and cancer over years. This means a patient with visible warts has HPV infection that is unlikely to cause cancer, while a patient with an abnormal smear (high-risk HPV) may have no visible genital lesions at all. The clinical implication: treating visible warts does not reduce the risk of cervical or other anogenital cancers — the NHS Cervical Screening Programme is the key cancer prevention tool.

The urethral meatus examination for warts is often omitted but important — intraurethral warts (extending into the urethra) are present in approximately 5–8% of men with penile warts and require specialist treatment (urethroscopy + podophyllin/laser). Clinical indication: warts visible at the urethral meatus, haematuria, urethral discharge, or dysuria with warts. Routine proctoscopy for perianal warts is not recommended in primary care — anoscopy for intra-anal warts is a GUM/colorectal procedure. However, perianal warts should be documented and the patient should be asked about intra-anal symptoms (bleeding, discharge) which would trigger GUM referral for internal examination. The co-STI testing principle: warts indicate skin-to-skin sexual contact and HPV acquisition — the same sexual exposure that caused HPV may have also caused Chlamydia, GC, syphilis, or HIV. All patients with new anogenital warts should be offered a full STI screen, ideally at GUM (multi-site sampling for MSM is particularly important). In primary care, a full screen including HIV and syphilis serology can be arranged, with referral to GUM for any positive results.

Condylomata lata (secondary syphilis) is the most important clinical mimic of anogenital warts — it produces broad-based, flat, moist, grey-white condylomata-like papules at mucosal junctions, particularly the perianal and vulval areas. Unlike condylomata acuminata (which are pedunculated or papillomatous), condylomata lata are smooth, flat, and tend to coalesce. They are teeming with Treponema pallidum and are highly infectious. Missing this diagnosis has two consequences: (1) the patient does not receive treatment for systemic syphilis (which at the secondary stage has already disseminated and can cause cardiovascular, neurological, and ocular damage); (2) sexual contacts are not notified and treated. TPHA + RPR serology should be performed at every new anogenital lesion presentation regardless of the clinical appearance.

GUM clinic referral for all new anogenital wart presentations is the BASHH standard — it ensures: full STI co-testing (including multi-site NAAT for MSM), appropriate treatment selection (GUM nurses trained in cryotherapy, TCA, podophyllotoxin application), partner notification support, and documentation. GP management is appropriate when GUM access is limited or the patient declines referral, but the standard of care is GUM for the initial assessment. Warts in pregnancy: condylomata acuminata proliferate during pregnancy (due to immune modulation and increased vascularity) and can become very extensive by the third trimester. Large warts near the introitus can obstruct delivery and should be managed proactively from the second trimester. Podophyllotoxin is contraindicated in pregnancy (teratogenic). Imiquimod: insufficient safety data. Trichloroacetic acid (TCA) is the safest topical option in pregnancy. Cryotherapy is also safe. Caesarean section for wart-related obstruction of the birth canal is occasionally required. Refer to GUM or gynaecology early in pregnant women with warts.

The imiquimod local inflammation education is a critical patient safety point — imiquimod works by stimulating local innate immune responses (via Toll-like receptor 7 activation), causing local erythema, swelling, erosion, and sometimes ulceration at the treatment site. Most patients interpret this inflammatory response as a side effect or adverse reaction and stop the treatment prematurely — this is the most common reason for imiquimod treatment failure. The GP must explicitly tell the patient: 'You will notice redness, swelling, and possibly some skin breakdown where you apply it — this is the treatment working, not a problem. If it's very severe, use less or apply less frequently, but some inflammation is expected and is a sign it's working.' Severity of local reaction correlates with treatment efficacy. The 6–10 hour overnight application instruction is also critical — if left on for too long, severe local tissue damage can occur. Set a phone alarm to wake up and wash off the cream.

The psychosexual impact of anogenital wart diagnosis is frequently underestimated by clinicians and routinely underaddressed in consultations — multiple studies show that HPV diagnosis is associated with significant psychological distress, including shame, guilt, concerns about infidelity (patients frequently assume the diagnosis implies their partner has been unfaithful), and anxiety about cancer and future fertility. The key clinical communication point is: HPV is the most common STI globally (80% of sexually active people will acquire HPV at some point), it is transmitted through skin-to-skin contact even with condom use, visible warts are caused by low-risk types that do NOT cause cancer, and the infection is often dormant for months to years before becoming visible — so the appearance of warts does not necessarily indicate recent acquisition or a new partner. Taking 3 minutes to address these concerns explicitly and specifically (rather than just treating the lesions) dramatically reduces patient anxiety and improves treatment adherence.

Anal cancer prevention in MSM and HIV-positive patients deserves specific emphasis as a primary care screening responsibility — the incidence of anal SCC in HIV-positive MSM is approximately 100 per 100,000 (compared to 2 per 100,000 in the general population), driven by HPV 16/18 persistent infection in the anal transformation zone. Several UK centres (notably the ANCHOR study group) have established high-resolution anoscopy (HRA) programmes for anal dysplasia surveillance in high-risk patients. GPs managing HIV-positive MSM or MSM with extensive anogenital warts should be aware of these programmes and refer to GUM for anal cytology assessment. The ANCHOR trial (2021) showed that treatment of anal high-grade squamous intraepithelial lesions (HSIL) in HIV-positive individuals reduces anal SCC risk by approximately 57% — making anal dysplasia surveillance and treatment a proven cancer prevention strategy.

The recurrence counselling after wart clearance is an important patient safety and relationship safeguarding conversation — patients who have cleared their warts and then develop a recurrence within weeks or months often assume their partner has been re-infecting them, leading to relationship conflict and unfounded accusations. The accurate information is: HPV can persist in the basal epithelial layer in a latent state after clinical clearance, and can reactivate when local immunity is temporarily suppressed (illness, stress, antibiotic use, disrupted sleep, alcohol). Recurrence within 6 months of clearance almost always represents reactivation of the same HPV infection, not re-infection from a partner. After 12 months of recurrence-free clearance, the risk of reactivation falls substantially — most virological clearance occurs within 2 years. This information prevents avoidable relationship harm and should be given proactively at the follow-up visit after initial clearance.